Drugs / ripertamab
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02206308 | May 2012 → Jul 2013 | B-cell non-Hodgkin lymphoma | Sinocelltech Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07372807 | Feb 2026 → Dec 2027 expected | myasthenia gravis | Zhongming Qiu | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02456207 | May → Dec 2015 | B-cell non-Hodgkin lymphoma | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06858722 | Mar 2025 → Jun 2027 expected | polyneuropathy, inflammatory demyelinating, chronic | Zhongming Qiu | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT02772822 | Jun 2016 → Jun 2019 | diffuse large B-cell lymphoma | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06790888 | Feb 2025 → Dec 2027 expected | autoimmune thrombocytopenia | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06405100 Comparator | May 2024 → Apr 2026 overdue | minimal change disease | Air Force Military Medical University, China | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07388810 Comparator | Feb → Dec 2026 expected | — | Mao Jianhua | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ripertamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06790888 ↗ |
| Known as | SCT400 | “Three escalating single-dose groups of chimeric anti-CD20 monoclonal antibody(SCT400) : 250 mg/m2 , 375 mg/m2，500 mg/m2, once a week for 4 doses;” NCT02206308 ↗ |
| Modality | Monoclonal antibody | “chimeric anti-CD20 monoclonal antibody(SCT400)” NCT02206308 ↗ |
| Route | Intravenous | “SCT400:375 mg/m2, iv, one infusion” NCT02456207 ↗ |